By JEFFREY L. WILKINSAssociated PressWASHINGTON (AP) — A medicine that works to help people who are sick with heart disease and stroke may save your own life.
Researchers are using the drug ritonavir to treat a rare form of brain cancer and found it was more effective than existing therapies in reducing seizures in mice.
In a study published in the journal Nature Medicine, the researchers at the University of Maryland found ritonivir reduced seizures in mouse models of a rare but aggressive form of cancer called myeloid leukemia (ML).ML is a tumor that is hard to treat and can spread to other parts of the body, causing cancer and death.
The drug, known as pembrolizumab, has been approved by the Food and Drug Administration for patients ages 18 and older.
It is also approved for treatment of a type of cancer known as non-Hodgkin lymphoma.
The researchers looked at ritonovir, which is approved for use in humans by the U.S. Food and Safety and Drug administration, in mice with a variant of ML called the non-myeloid-leukemia-associated (NMLA) variant.
The NMLA variant has been linked to a significantly higher risk of cancer, including lung cancer, kidney cancer, pancreatic cancer and other cancers.
It is the most common form of ML.
In the new study, the scientists used a mouse model of ML to compare ritonvirus-based drugs against two other drugs that were approved in the U, one of which is ritonvir.
The drugs were approved for treating a variant known as NMLA, which has been associated with a higher risk for cancer, and ritonviroluzole, a drug that works in mice to treat other types of leukemia.
The NMLA virus was not tested in the new mice.
The mice that received the drug fared better on the tests used to determine their survival rates compared with the mice that did not receive the drug.
The results were not statistically significant, but were better than what the researchers found for other drugs approved for other cancer types.
The results may mean that ritonvasvir can be used to treat the NMLA variants in people, said lead author Dr. Sarah T. Nesbitt, an associate professor of medicine at the MD Anderson Cancer Center in Houston.
The study does not show ritonveravir is a safe drug for people with NMLA or any other cancer, she said.
The new study was conducted in a mouse strain of ML that has not been used before, and it is the first time scientists have tested a drug in the human population with that variant of the virus.
Scientists have known for years that rionavir works to stop the growth of the cancerous cells that form tumors.
They believe the drug is able to help stem cell tumors.
The new study shows that riotavir also has the ability to kill cancer cells that have formed in a patient’s bloodstream.
The researchers said the new drug also reduced seizures and the amount of blood loss caused by the disease.
The seizure-reduction drug, which also is used to help reduce seizures in people with epilepsy, has already been used to save people with multiple sclerosis and other neurological disorders.
The treatment was given to mice in a laboratory and then compared to the current drugs approved by FDA.
The next step will be to determine whether the drugs work in humans, said Nesbin, who is also affiliated with the National Institutes of Health.
It will also be important to see if the drugs are safe and effective in humans.
The NIH did not immediately respond to a request for comment.
The National Institutes, the Food & Drug Administration and the U of M were not immediately available to comment.
Copyright 2018 The Associated Press.
All rights reserved.
This material may not be published, broadcast, rewritten or redistributed without permission.